trial

Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia

NCTId NCT01095562
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 207 (actual)
Sponsored by AbbVie
Primary completion 2011-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
207 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2010-03
Primary completion
2011-08
Eligibility
ALL · 20 Years · 55 Years

Interventions & indications

Drugs
ABT-126

Sponsors

AbbVieLead Sponsor

Investigators

1
George Haig, PharmDStudy Director

Sites

23 total
Cerritos, United StatesCosta Mesa, United StatesEscondido, United StatesGarden Grove, United StatesGranada Hills, United StatesOceanside, United StatesSan Bernardino, United StatesSan Diego, United StatesSanta Ana, United StatesSanta Ana, United StatesTorrance, United StatesTampa, United States

Linked catalysts

1
Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizoph — primary completion2011-08

Facts & assertions

4 sourced
Enrollment
207
Phase
PHASE2
Primary Completion Date
2011-08
Status
COMPLETED
relationships
The graph out of here
drug
ABT-126
drug
lead_sponsor
AbbVie
company
indication
Cognitive Deficits in Schizophrenia
indication
investigator
George Haig, PharmD
person